{"id":70869,"date":"2026-07-29T18:16:09","date_gmt":"2026-07-29T10:16:09","guid":{"rendered":"https:\/\/flcube.com\/?p=70869"},"modified":"2026-07-29T18:16:10","modified_gmt":"2026-07-29T10:16:10","slug":"chinas-cde-tightens-drug-review-standards-with-new-no-supplemental-data-rule-for-major-deficiencies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70869","title":{"rendered":"China&#8217;s CDE Tightens Drug Review Standards with New &#8220;No Supplemental Data&#8221; Rule for Major Deficiencies"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>Center for Drug Evaluation (CDE)<\/strong> of China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> released a revised draft of the <strong>Standards for Written Deficiency Communications in Drug Review<\/strong> for public comment, introducing a significant policy shift that eliminates opportunities for supplemental data submission in cases involving major deficiencies.<\/p>\n\n\n\n<h2 id=\"h-regulatory-framework-update\" class=\"wp-block-heading\">Regulatory Framework Update<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>Center for Drug Evaluation (CDE), NMPA<\/td><\/tr><tr><td><strong>Document<\/strong><\/td><td>Standards for Written Deficiency Communications in Drug Review (Revised Draft)<\/td><\/tr><tr><td><strong>Release Date<\/strong><\/td><td>24 Jul 2026<\/td><\/tr><tr><td><strong>Previous Version<\/strong><\/td><td>Included in Procedures for Supplemental Data Submission (Trial), No. 42 of 2020 (November 2020)<\/td><\/tr><tr><td><strong>Comment Period<\/strong><\/td><td>Currently open for public feedback<\/td><\/tr><tr><td><strong>Key Change<\/strong><\/td><td>Elimination of supplemental data requests for major deficiencies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-key-revisions-amp-policy-changes\" class=\"wp-block-heading\">Key Revisions &amp; Policy Changes<\/h2>\n\n\n\n<h3 id=\"h-deficiency-classification-clarity\" class=\"wp-block-heading\">Deficiency Classification Clarity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Severity Designation:<\/strong> Addresses ambiguous descriptions of defect severity that previously failed to clearly designate deficiencies as &#8220;major or minor&#8221;<\/li>\n\n\n\n<li><strong>Major Deficiency Definition:<\/strong> Provides clearer criteria for what constitutes a &#8220;major&#8221; deficiency in drug applications<\/li>\n\n\n\n<li><strong>Standardization:<\/strong> Harmonizes deficiency communication language across different review divisions<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-new-no-supplemental-data-provision\" class=\"wp-block-heading\">New &#8220;No Supplemental Data&#8221; Provision<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The most significant change introduces a <strong>catch-all provision<\/strong> stating:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">&#8220;If the Center for Drug Evaluation identifies major deficiencies during the review process, it shall no longer request the applicant to submit supplemental data, and shall render a negative approval decision based on the submitted application materials as already on file.&#8221;<\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\">This represents a fundamental shift from the previous approach, which allowed applicants multiple opportunities to address deficiencies through supplemental submissions.<\/p>\n\n\n\n<h3 id=\"h-impact-on-review-process\" class=\"wp-block-heading\">Impact on Review Process<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficiency Focus:<\/strong> Streamlines the review process by eliminating lengthy back-and-forth communications for fundamentally flawed applications<\/li>\n\n\n\n<li><strong>Quality Emphasis:<\/strong> Places greater responsibility on applicants to submit complete, high-quality applications initially<\/li>\n\n\n\n<li><strong>Timeline Predictability:<\/strong> Reduces uncertainty in approval timelines by establishing clear decision points<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-industry-implications\" class=\"wp-block-heading\">Industry Implications<\/h2>\n\n\n\n<h3 id=\"h-for-pharmaceutical-companies\" class=\"wp-block-heading\">For Pharmaceutical Companies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Higher Stakes:<\/strong> Initial application quality becomes critical, as major deficiencies will result in immediate rejection without opportunity for correction<\/li>\n\n\n\n<li><strong>Resource Allocation:<\/strong> Companies may need to invest more heavily in pre-submission consultation and internal quality assurance processes<\/li>\n\n\n\n<li><strong>Strategic Planning:<\/strong> Development programs must ensure comprehensive data packages that anticipate potential regulatory concerns<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-regulatory-strategy\" class=\"wp-block-heading\">For Regulatory Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pre-Submission Meetings:<\/strong> Increased importance of formal meetings with CDE to clarify requirements and expectations before filing<\/li>\n\n\n\n<li><strong>Gap Analysis:<\/strong> Enhanced need for thorough gap analysis against current regulatory standards before submission<\/li>\n\n\n\n<li><strong>Risk Assessment:<\/strong> More rigorous internal risk assessment of potential major deficiency areas<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This regulatory tightening aligns with China&#8217;s broader pharmaceutical regulatory modernization efforts, which have increasingly emphasized international harmonization and efficiency. The change mirrors approaches used by other major regulatory agencies, including the FDA and EMA, which also limit opportunities for addressing major deficiencies post-submission.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts estimate that this change could impact 15-20% of drug applications that historically relied on supplemental data submissions to address significant issues identified during review.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory policy changes. The draft standards are subject to public comment and may be modified before final implementation. Actual regulatory outcomes and industry impacts may differ due to policy revisions, stakeholder feedback, and implementation details.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) of China&#8217;s National Medical Products Administration (NMPA) released a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[102,14],"class_list":["post-70869","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-cde","tag-nmpa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s CDE Tightens Drug Review Standards with New &quot;No Supplemental Data&quot; Rule for Major Deficiencies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) released a revised draft of the Standards for Written Deficiency Communications in Drug Review for public comment, introducing a significant policy shift that eliminates opportunities for supplemental data submission in cases involving major deficiencies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70869\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s CDE Tightens Drug Review Standards with New &quot;No Supplemental Data&quot; Rule for Major Deficiencies\" \/>\n<meta property=\"og:description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) released a revised draft of the Standards for Written Deficiency Communications in Drug Review for public comment, introducing a significant policy shift that eliminates opportunities for supplemental data submission in cases involving major deficiencies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70869\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T10:16:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-29T10:16:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70869#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70869\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s CDE Tightens Drug Review Standards with New &#8220;No Supplemental Data&#8221; Rule for Major Deficiencies\",\"datePublished\":\"2026-07-29T10:16:09+00:00\",\"dateModified\":\"2026-07-29T10:16:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70869\"},\"wordCount\":510,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CDE\",\"NMPA\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70869#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70869\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70869\",\"name\":\"China's CDE Tightens Drug Review Standards with New \\\"No Supplemental Data\\\" Rule for Major Deficiencies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-29T10:16:09+00:00\",\"dateModified\":\"2026-07-29T10:16:10+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released a revised draft of the Standards for Written Deficiency Communications in Drug Review for public comment, introducing a significant policy shift that eliminates opportunities for supplemental data submission in cases involving major deficiencies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70869#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70869\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70869#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s CDE Tightens Drug Review Standards with New &#8220;No Supplemental Data&#8221; Rule for Major Deficiencies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's CDE Tightens Drug Review Standards with New \"No Supplemental Data\" Rule for Major Deficiencies - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released a revised draft of the Standards for Written Deficiency Communications in Drug Review for public comment, introducing a significant policy shift that eliminates opportunities for supplemental data submission in cases involving major deficiencies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70869","og_locale":"en_US","og_type":"article","og_title":"China's CDE Tightens Drug Review Standards with New \"No Supplemental Data\" Rule for Major Deficiencies","og_description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released a revised draft of the Standards for Written Deficiency Communications in Drug Review for public comment, introducing a significant policy shift that eliminates opportunities for supplemental data submission in cases involving major deficiencies.","og_url":"https:\/\/flcube.com\/?p=70869","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-29T10:16:09+00:00","article_modified_time":"2026-07-29T10:16:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70869#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70869"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s CDE Tightens Drug Review Standards with New &#8220;No Supplemental Data&#8221; Rule for Major Deficiencies","datePublished":"2026-07-29T10:16:09+00:00","dateModified":"2026-07-29T10:16:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70869"},"wordCount":510,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CDE","NMPA"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70869#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70869","url":"https:\/\/flcube.com\/?p=70869","name":"China's CDE Tightens Drug Review Standards with New \"No Supplemental Data\" Rule for Major Deficiencies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-29T10:16:09+00:00","dateModified":"2026-07-29T10:16:10+00:00","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released a revised draft of the Standards for Written Deficiency Communications in Drug Review for public comment, introducing a significant policy shift that eliminates opportunities for supplemental data submission in cases involving major deficiencies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70869#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70869"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70869#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s CDE Tightens Drug Review Standards with New &#8220;No Supplemental Data&#8221; Rule for Major Deficiencies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70869"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70869\/revisions"}],"predecessor-version":[{"id":70870,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70869\/revisions\/70870"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}